SlideShare a Scribd company logo
S62	 The Journal of Heart and Lung Transplantation, Vol 34, No 4S, April 2015
better understand the degree and type of mismatches that impact transplant
survival.

(147)
MELD-XI Score Predicts Early and Late Mortality in Patients Following
Heart Transplantation
J.C. Grimm ,1 J. Magruder,1 V. Valero 3rd,1 A. Kilic,1 G.J. Whitman,1
R.J. Tedford,2 S.D. Russell,2 A.S. Shah,1 C.M. Sciortino.1  1Surgery,
The Johns Hopkins Medical Institution, Baltimore, MD; 2Medicine,
The Johns Hopkins Medical Institution, Baltimore, MD.
Purpose: The Model for End-stage Liver Disease eXcluding INR (MELD-XI)
score has been validated as an accurate predictor of outcomes in heart fail-
ure patients, but its utility in orthotopic heart transplant (OHT) recipients is
unknown. Accordingly, we sought to determine the risk-adjusted influence
of an elevated MELD-XI score on early and late mortality following OHT.
Methods: The United Network for Organ Sharing database was queried
for adult ( 18 years) patients undergoing OHT between 2002 and 2012.
A MELD-XI score (incorporating serum creatinine and bilirubin) was cal-
culated. Stratification into “high” and “low” MELD-XI cohorts based on a
previously established threshold score of 17 was performed. Patient specific
characteristics, intraoperative variables and postoperative outcomes were
compared between the two cohorts. Thirty-day, 1-year and 5-year multi-
variable Cox hazard regression models were constructed to determine the
risk-adjusted impact of a “high” MELD-XI score on mortality. Kaplan Meier
estimates were utilized to compare unadjusted survival.
Results: Of the 27,126 patients that met criteria for inclusion, 22% (6,048)
had MELD-XI scores  17. Thirty-day (p 0.001), 1-year (p 0.001) and
5-year (p 0.001) survival was statistically different between the score cohorts.
Additionally, a “high” MELD-XI score was an independent predictor of 30-day
(HR: 1.75, CI: 1.52-2.02; p 0.001), 1-year (HR: 1.62, CI: 1.48-1.77; p 0.001)
and 5-year (HR: 1.33, CI: 1.25-1.43; p 0.001) mortality after adjustment with
a combination of recipient, donor and transplant specific variables. This cohort
also experienced an increased incidence of postoperative renal failure (11.7%
v. 6.5%; p 0.001) and stroke (3.3% v. 2.2%; p 0.001).
Conclusion: This is the largest known study demonstrating the unique appli-
cation of the MELD-XI scoring system in predicting early and late mortality
in patients following OHT. The MELD-XI provides another preoperative
metric to improve patient selection and, thus, optimize organ allocation.
(148)
Restoration of Pulsatile Flow Leads to a Reduction in Sympathetic
Nerve Activity Among Patients With Continuous-Flow Left Ventricular
Assist Devices
W.K. Cornwell ,1 T. Tarumi,2 A. Stickford,2 J. Kibe,3 C. Fitzsimmons,3
J. Moore,2 M. Roberts,2 R. Parker,2 D. Markham,4 M. Drazner,1
B. Levine.2  1Cardiology, Univ of Texas SW, Dallas, TX; 2Institute of
Exercise and Environmental Medicine, Dallas, TX; 3Cardiology, Univ of
Texas SW, Coppell, TX; 4Cardiology, Emory University, Atlanta, GA.
Purpose: We previously demonstrated that sympathetic nerve activity (SNA)
is markedly elevated in patients with continuous-flow (CF) left ventricular
assist devices (LVADs). In the current study, we sought to determine whether
the restoration of pulsatile flow leads to reductions in SNA in these patients.
Methods: Eight male and two female subjects (56±11 years) with Heartmate
II, CF-LVADs underwent hemodynamic and sympathetic neural assessment.
Beat-to-beat blood pressure and muscle (M) SNA, (measured directly via
microneurography) were continuously recorded to determine steady-state
(145)
Cardiac Allograft Vasculopathy in Redo-Transplants: Is It More or Less
(or) the Same the Second Time around?
L. McCreath , R. McCubrey, J. Folsom, S. Wright, J. Stehlik, D. Budge,
S.H. McKellar, M. Everitt, G. Snow, B. Reid, K. Skedros, A. Ragnhildstveit,
K. Afshar, J. Nativi, S.G. Drakos, A.G. Kfoury.  UTAH Cardiac Transplant
Program, Salt Lake City, UT.
Purpose: CardiacAllograftVasculopathy (CAV) continues to hinder the long
term success of heart transplant recipients. Redo-transplantation is currently
the only definitive treatment for advanced CAV. Whether these patients are at
similar CAV-risk with the second transplant remains unknown and the topic
of interest in this study.
Methods: The UTAH Cardiac Transplant database was queried for all patients
who were retransplanted from 1985 to 2011. Heart recipients who did not
have CAV as an indication for redo-transplantation were excluded. CAV
diagnosis was made by coronary angiography and based on the 2010 ISHLT
standardized nomenclature for CAV. Patient demographics, rejection history,
and CAV incidence were analyzed.
Results: Of the 1,169 eligible patients, 135 (11.5%) developed CAV post their
first transplant; 78 cases within 10 years and 54 beyond 10 years. The mean
time to CAV was 6.58 years. Of the 135 patients who developed CAV, only 21
(15.5%)endeduprequiringaredo-transplant. Of the 21 patients retransplanted,4
(19.0%) developed CAV again; 2 patients within 10 years and 2 patients beyond
10 years.The incidence of CAV was statistically similar (p= NS) between 1st and
redo-transplant. Baseline characteristics (see table) are included.
Conclusion: Our results indicate that CAV is as likely to develop in redo-
transplants despite recent advances in immunosuppression and the standard-
ized use of lipid-lowering agents.Although outcomes in redo-transplantation
for the indication of CAV are favorable, efforts to better understand and
minimize CAV are needed, especially in the face of scarce donor organs.

(146)
Influence of HLA Mismatch on Outcomes After Heart Transplantation:
UNOS Registry Data
K. Pandya , J. Zhang, M. Hickey, A. Nsair, A. Baas, M. Cadeiras, D. Cruz,
L. Reardon, M. Deng, A. Ardehali, E. Reed, E. Depasquale.  Advanced
Heart Failure and Cardiac Transplantation, University of California,
Los Angeles, Los Angeles, CA.
Purpose: HLA matching has been shown to improve survival in renal trans-
plants, however, is not currently a major consideration in heart transplanta-
tion (HT). We sought to evaluate the impact of HLA mismatch on long term
outcomes after heart transplantation.
Methods: 37516 patients were identified from the UNOS registry (1987-
2014) and stratified by number of HLA mismatches ( 3 vs ≤ 3). Exclusions:
age  18, multiorgan or re-HT. Survival was censored at 12-y. Multivariate
Cox proportional hazard regression models were adjusted for age, sex, DM,
race, ischemic time, dialysis, etiology, life support and wait times.
Results: 5791 were identified with ≤ 3 HLA mismatches compared to
31720 with  3 HLA mismatches. Mean age was 52.1 ± 11.7 years (p= NS
between groups). Most common etiologies were dilated (42%) and ischemic
cardiomyopathy (41%). Mean follow up was 6.4 ± 5.6 years. Number of
mismatches by HLA loci ( 3 vs ≤ 3): A Locus [1.5 ± 0.6 vs 0.7 ± 0.6], B
Locus [1.8 ± 0.4 vs 1.1 ±0.6] and DR Locus [1.6 ± 0.5 vs 0.9 ± 0.6] (p 3,
respectively). Crude 1, 5, 10 year survival was: HLA mismatch ≤ 3 [88, 73,
52%] vs HLA mismatch  3 [87, 71, 51%] (log-rank, p= 0.006). Multivariate
Cox regression analysis yielded a hazard ratio of 1.07 (CI 1.02 -1.12).
Conclusion: HT recipients with fewer mismatches appear to have small
but significantly improved outcomes. Further study is warranted to

More Related Content

What's hot

DANISH trial (Cardiology)
 DANISH trial (Cardiology) DANISH trial (Cardiology)
DANISH trial (Cardiology)
PRAVEEN GUPTA
 
immunotherapy for multiple myeloma
immunotherapy for multiple myelomaimmunotherapy for multiple myeloma
immunotherapy for multiple myeloma
spa718
 
Dallas criteria Circulation 2006
Dallas criteria Circulation 2006Dallas criteria Circulation 2006
Dallas criteria Circulation 2006
gisa_legal
 
Year in cardiology - ACS
Year in cardiology - ACSYear in cardiology - ACS
Year in cardiology - ACS
Praveen Nagula
 
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
CTSI at UCSF
 
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
Kevin Jaglinski
 
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
spa718
 
Advancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular diseaseAdvancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular disease
AdvancingDialysis.org
 
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdrThe role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
Alexandria University, Egypt
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yan
spa718
 
Prami trial
Prami trialPrami trial
Prami trial
Praveen Nagula
 
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
crimsonpublishersOJCHD
 
Cv lprit substudy
Cv lprit substudyCv lprit substudy
Cv lprit substudy
Iqbal Dar
 
nejmoa1911481.pdf
nejmoa1911481.pdfnejmoa1911481.pdf
nejmoa1911481.pdf
CarlosRonaldoQuispeE
 
Advancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular diseaseAdvancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular disease
AdvancingDialysis.org
 
Cell Salvage in PBM
Cell Salvage in PBMCell Salvage in PBM
Cell Salvage in PBM
Testa Emanuela
 
Journal Club 1: The Prami Trial
Journal Club 1: The Prami TrialJournal Club 1: The Prami Trial
Journal Club 1: The Prami Trial
SCAIF
 
High Risk Lymphoma
High Risk LymphomaHigh Risk Lymphoma
High Risk Lymphoma
spa718
 
Ppci culprit vs mv acad card 2013 mumbai
Ppci culprit vs mv acad card 2013 mumbaiPpci culprit vs mv acad card 2013 mumbai
Ppci culprit vs mv acad card 2013 mumbai
cardiositeindia
 
Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...
AdvancingDialysis.org
 

What's hot (20)

DANISH trial (Cardiology)
 DANISH trial (Cardiology) DANISH trial (Cardiology)
DANISH trial (Cardiology)
 
immunotherapy for multiple myeloma
immunotherapy for multiple myelomaimmunotherapy for multiple myeloma
immunotherapy for multiple myeloma
 
Dallas criteria Circulation 2006
Dallas criteria Circulation 2006Dallas criteria Circulation 2006
Dallas criteria Circulation 2006
 
Year in cardiology - ACS
Year in cardiology - ACSYear in cardiology - ACS
Year in cardiology - ACS
 
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...
 
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
A_Rapid_Noninvasive_Assay_for_the_Detection_of 2013 96_17
 
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
Donor Lymphocyte Infusion in Patients with Hematological Malignancies after T...
 
Advancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular diseaseAdvancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular disease
 
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdrThe role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
The role of d dimer in the diagnosis of left atrial appendage thrombus . jcdr
 
Donor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua YanDonor Lymphocyte Infusion: Dr. Chenhua Yan
Donor Lymphocyte Infusion: Dr. Chenhua Yan
 
Prami trial
Prami trialPrami trial
Prami trial
 
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
Short Term Outcomes after Use of Intracardiac Bone Stem Cell Transplantation ...
 
Cv lprit substudy
Cv lprit substudyCv lprit substudy
Cv lprit substudy
 
nejmoa1911481.pdf
nejmoa1911481.pdfnejmoa1911481.pdf
nejmoa1911481.pdf
 
Advancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular diseaseAdvancing dialysis: Recasting kidney failure as cardiovascular disease
Advancing dialysis: Recasting kidney failure as cardiovascular disease
 
Cell Salvage in PBM
Cell Salvage in PBMCell Salvage in PBM
Cell Salvage in PBM
 
Journal Club 1: The Prami Trial
Journal Club 1: The Prami TrialJournal Club 1: The Prami Trial
Journal Club 1: The Prami Trial
 
High Risk Lymphoma
High Risk LymphomaHigh Risk Lymphoma
High Risk Lymphoma
 
Ppci culprit vs mv acad card 2013 mumbai
Ppci culprit vs mv acad card 2013 mumbaiPpci culprit vs mv acad card 2013 mumbai
Ppci culprit vs mv acad card 2013 mumbai
 
Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...
 

Similar to Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) the Same the Second Time around?

Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery
ProActive Capital Resources Group
 
Stress echo and aortic stenosis
Stress echo and aortic stenosisStress echo and aortic stenosis
Stress echo and aortic stenosis
Cardiovascular Diagnosis and Therapy (CDT)
 
International Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & DiagnosisInternational Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & Diagnosis
SciRes Literature LLC. | Open Access Journals
 
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
semualkaira
 
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
semualkaira
 
Are we ready to implant LVAD’s in the less sick?
Are we ready to implant LVAD’s in the less sick?Are we ready to implant LVAD’s in the less sick?
Are we ready to implant LVAD’s in the less sick?
RashadZayat1
 
Columbia-Research
Columbia-ResearchColumbia-Research
Columbia-Research
Anya Ragnhildstveit
 
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Premier Publishers
 
Future is in heart transplantation
Future is in heart transplantationFuture is in heart transplantation
Future is in heart transplantation
drucsamal
 
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
Ingrid Abrahamsen, MS, CCRP
 
Abstract world congress
Abstract world congressAbstract world congress
Abstract world congress
Sergio Pinski
 
Factors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operatedFactors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operated
Dr. Murtaza Kamal MD,DNB,DrNB Ped Cardiology
 
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
carlofino
 
Cell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't workCell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't work
drucsamal
 
Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...
Paul Schoenhagen
 
CCTGA dobutamine
CCTGA dobutamineCCTGA dobutamine
CCTGA dobutamine
Ali Dodge-Khatami, MD, PhD
 
1428931228
14289312281428931228
1428931228
Sanjay2176
 
Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025
Kayla Twomey
 
HCM SCD.pptx
HCM SCD.pptxHCM SCD.pptx
HCM SCD.pptx
Aatish Rengan
 
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Duke Heart
 

Similar to Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) the Same the Second Time around? (20)

Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery
 
Stress echo and aortic stenosis
Stress echo and aortic stenosisStress echo and aortic stenosis
Stress echo and aortic stenosis
 
International Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & DiagnosisInternational Journal of Cardiovascular Diseases & Diagnosis
International Journal of Cardiovascular Diseases & Diagnosis
 
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
 
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
The Impact of Lymph Node Dissection on Survival in Intermediate- and High-Ris...
 
Are we ready to implant LVAD’s in the less sick?
Are we ready to implant LVAD’s in the less sick?Are we ready to implant LVAD’s in the less sick?
Are we ready to implant LVAD’s in the less sick?
 
Columbia-Research
Columbia-ResearchColumbia-Research
Columbia-Research
 
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
 
Future is in heart transplantation
Future is in heart transplantationFuture is in heart transplantation
Future is in heart transplantation
 
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
 
Abstract world congress
Abstract world congressAbstract world congress
Abstract world congress
 
Factors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operatedFactors determining outcomes in grown up patients operated
Factors determining outcomes in grown up patients operated
 
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
Prognostic Value of Right Ventricular Parameters in Patients with Left Ventri...
 
Cell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't workCell therapies in heart failure thet don't work
Cell therapies in heart failure thet don't work
 
Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...Impact of statins and beta-blocker therapy on mortality after coronary artery...
Impact of statins and beta-blocker therapy on mortality after coronary artery...
 
CCTGA dobutamine
CCTGA dobutamineCCTGA dobutamine
CCTGA dobutamine
 
1428931228
14289312281428931228
1428931228
 
Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025
 
HCM SCD.pptx
HCM SCD.pptxHCM SCD.pptx
HCM SCD.pptx
 
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
Genetic Cardiomyopathy & Sarcoidosis Clinic: Is There Room to Subspecialize?
 

Cardiac Allograft Vasculopathy in Redo-Transplants- Is It More or Less (or) the Same the Second Time around?

  • 1. S62 The Journal of Heart and Lung Transplantation, Vol 34, No 4S, April 2015 better understand the degree and type of mismatches that impact transplant survival. (147) MELD-XI Score Predicts Early and Late Mortality in Patients Following Heart Transplantation J.C. Grimm ,1 J. Magruder,1 V. Valero 3rd,1 A. Kilic,1 G.J. Whitman,1 R.J. Tedford,2 S.D. Russell,2 A.S. Shah,1 C.M. Sciortino.1  1Surgery, The Johns Hopkins Medical Institution, Baltimore, MD; 2Medicine, The Johns Hopkins Medical Institution, Baltimore, MD. Purpose: The Model for End-stage Liver Disease eXcluding INR (MELD-XI) score has been validated as an accurate predictor of outcomes in heart fail- ure patients, but its utility in orthotopic heart transplant (OHT) recipients is unknown. Accordingly, we sought to determine the risk-adjusted influence of an elevated MELD-XI score on early and late mortality following OHT. Methods: The United Network for Organ Sharing database was queried for adult ( 18 years) patients undergoing OHT between 2002 and 2012. A MELD-XI score (incorporating serum creatinine and bilirubin) was cal- culated. Stratification into “high” and “low” MELD-XI cohorts based on a previously established threshold score of 17 was performed. Patient specific characteristics, intraoperative variables and postoperative outcomes were compared between the two cohorts. Thirty-day, 1-year and 5-year multi- variable Cox hazard regression models were constructed to determine the risk-adjusted impact of a “high” MELD-XI score on mortality. Kaplan Meier estimates were utilized to compare unadjusted survival. Results: Of the 27,126 patients that met criteria for inclusion, 22% (6,048) had MELD-XI scores  17. Thirty-day (p 0.001), 1-year (p 0.001) and 5-year (p 0.001) survival was statistically different between the score cohorts. Additionally, a “high” MELD-XI score was an independent predictor of 30-day (HR: 1.75, CI: 1.52-2.02; p 0.001), 1-year (HR: 1.62, CI: 1.48-1.77; p 0.001) and 5-year (HR: 1.33, CI: 1.25-1.43; p 0.001) mortality after adjustment with a combination of recipient, donor and transplant specific variables. This cohort also experienced an increased incidence of postoperative renal failure (11.7% v. 6.5%; p 0.001) and stroke (3.3% v. 2.2%; p 0.001). Conclusion: This is the largest known study demonstrating the unique appli- cation of the MELD-XI scoring system in predicting early and late mortality in patients following OHT. The MELD-XI provides another preoperative metric to improve patient selection and, thus, optimize organ allocation. (148) Restoration of Pulsatile Flow Leads to a Reduction in Sympathetic Nerve Activity Among Patients With Continuous-Flow Left Ventricular Assist Devices W.K. Cornwell ,1 T. Tarumi,2 A. Stickford,2 J. Kibe,3 C. Fitzsimmons,3 J. Moore,2 M. Roberts,2 R. Parker,2 D. Markham,4 M. Drazner,1 B. Levine.2  1Cardiology, Univ of Texas SW, Dallas, TX; 2Institute of Exercise and Environmental Medicine, Dallas, TX; 3Cardiology, Univ of Texas SW, Coppell, TX; 4Cardiology, Emory University, Atlanta, GA. Purpose: We previously demonstrated that sympathetic nerve activity (SNA) is markedly elevated in patients with continuous-flow (CF) left ventricular assist devices (LVADs). In the current study, we sought to determine whether the restoration of pulsatile flow leads to reductions in SNA in these patients. Methods: Eight male and two female subjects (56±11 years) with Heartmate II, CF-LVADs underwent hemodynamic and sympathetic neural assessment. Beat-to-beat blood pressure and muscle (M) SNA, (measured directly via microneurography) were continuously recorded to determine steady-state (145) Cardiac Allograft Vasculopathy in Redo-Transplants: Is It More or Less (or) the Same the Second Time around? L. McCreath , R. McCubrey, J. Folsom, S. Wright, J. Stehlik, D. Budge, S.H. McKellar, M. Everitt, G. Snow, B. Reid, K. Skedros, A. Ragnhildstveit, K. Afshar, J. Nativi, S.G. Drakos, A.G. Kfoury.  UTAH Cardiac Transplant Program, Salt Lake City, UT. Purpose: CardiacAllograftVasculopathy (CAV) continues to hinder the long term success of heart transplant recipients. Redo-transplantation is currently the only definitive treatment for advanced CAV. Whether these patients are at similar CAV-risk with the second transplant remains unknown and the topic of interest in this study. Methods: The UTAH Cardiac Transplant database was queried for all patients who were retransplanted from 1985 to 2011. Heart recipients who did not have CAV as an indication for redo-transplantation were excluded. CAV diagnosis was made by coronary angiography and based on the 2010 ISHLT standardized nomenclature for CAV. Patient demographics, rejection history, and CAV incidence were analyzed. Results: Of the 1,169 eligible patients, 135 (11.5%) developed CAV post their first transplant; 78 cases within 10 years and 54 beyond 10 years. The mean time to CAV was 6.58 years. Of the 135 patients who developed CAV, only 21 (15.5%)endeduprequiringaredo-transplant. Of the 21 patients retransplanted,4 (19.0%) developed CAV again; 2 patients within 10 years and 2 patients beyond 10 years.The incidence of CAV was statistically similar (p= NS) between 1st and redo-transplant. Baseline characteristics (see table) are included. Conclusion: Our results indicate that CAV is as likely to develop in redo- transplants despite recent advances in immunosuppression and the standard- ized use of lipid-lowering agents.Although outcomes in redo-transplantation for the indication of CAV are favorable, efforts to better understand and minimize CAV are needed, especially in the face of scarce donor organs. (146) Influence of HLA Mismatch on Outcomes After Heart Transplantation: UNOS Registry Data K. Pandya , J. Zhang, M. Hickey, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, E. Reed, E. Depasquale.  Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA. Purpose: HLA matching has been shown to improve survival in renal trans- plants, however, is not currently a major consideration in heart transplanta- tion (HT). We sought to evaluate the impact of HLA mismatch on long term outcomes after heart transplantation. Methods: 37516 patients were identified from the UNOS registry (1987- 2014) and stratified by number of HLA mismatches ( 3 vs ≤ 3). Exclusions: age  18, multiorgan or re-HT. Survival was censored at 12-y. Multivariate Cox proportional hazard regression models were adjusted for age, sex, DM, race, ischemic time, dialysis, etiology, life support and wait times. Results: 5791 were identified with ≤ 3 HLA mismatches compared to 31720 with  3 HLA mismatches. Mean age was 52.1 ± 11.7 years (p= NS between groups). Most common etiologies were dilated (42%) and ischemic cardiomyopathy (41%). Mean follow up was 6.4 ± 5.6 years. Number of mismatches by HLA loci ( 3 vs ≤ 3): A Locus [1.5 ± 0.6 vs 0.7 ± 0.6], B Locus [1.8 ± 0.4 vs 1.1 ±0.6] and DR Locus [1.6 ± 0.5 vs 0.9 ± 0.6] (p 3, respectively). Crude 1, 5, 10 year survival was: HLA mismatch ≤ 3 [88, 73, 52%] vs HLA mismatch  3 [87, 71, 51%] (log-rank, p= 0.006). Multivariate Cox regression analysis yielded a hazard ratio of 1.07 (CI 1.02 -1.12). Conclusion: HT recipients with fewer mismatches appear to have small but significantly improved outcomes. Further study is warranted to